TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11788637

Group type: EXPERIMENTAL
Intervention: 25 mg T enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 50 mg T enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 125 mg T enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 300 mg T enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 600 mg T enanthate
Number of subjects: 61

Group type: COMPARATOR
Intervention: GnRH agonist (control)
Number of subjects: 61
Study: 9872813

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microgram twice daily via Turbohaler)
Number of subjects: 14
Study: 8750401

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 1812149

Group type: EXPERIMENTAL
Intervention: Stretch-based relaxation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Postural relaxation/rest
Number of subjects: 34
Study: 6414252

Group type: EXPERIMENTAL
Intervention: Tocainide (750 mg bolus injection followed by oral therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine (conventional therapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 40
Study: 31712584

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg acute dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30388067

Group type: EXPERIMENTAL
Intervention: Shows rated TV-14
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Shows rated TV-MA
Number of subjects: 1220
Study: 27591918

Group type: EXPERIMENTAL
Intervention: Social Anxiety ABM
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Alcohol ABM
Number of subjects: 86

Group type: COMPARATOR
Intervention: Social Anxiety Control
Number of subjects: 86

Group type: COMPARATOR
Intervention: Alcohol Control
Number of subjects: 86
Study: 24569485

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (INS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Triple oral therapy (TOT) with metformin, glyburide, and pioglitazone
Number of subjects: 58
Study: 22150786

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 118

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 118
Study: 19013011

Group type: EXPERIMENTAL
Intervention: Combination therapy (tamsulosin 0.4 mg and dutasteride 0.5 mg)
Number of subjects: 4844

Group type: EXPERIMENTAL
Intervention: Dutasteride monotherapy
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 4844
Study: 18437789

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15894842

Group type: EXPERIMENTAL
Intervention: Unrestrained
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wrist restraint in front
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wrist restraint behind
Number of subjects: 12
Study: 12188237

Group type: COMPARATOR
Intervention: Fiberglass (FG) short leg casts
Number of subjects: 156

Group type: COMPARATOR
Intervention: Fiberglass (FG) short arm casts
Number of subjects: 156

Group type: COMPARATOR
Intervention: Plaster of Paris (POP) short leg casts
Number of subjects: 156

Group type: COMPARATOR
Intervention: Plaster of Paris (POP) short arm casts
Number of subjects: 156
Study: 9437310

Group type: EXPERIMENTAL
Intervention: ECCE/PC‐IOL
Number of subjects: 3400

Group type: COMPARATOR
Intervention: ICCE‐AG
Number of subjects: 3400
Study: 7652119

Group type: EXPERIMENTAL
Intervention: Intracranially recorded Mismatch Negativity (MMN) to tonal frequency changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracranially recorded MMN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-dependent N2 and P3 responses to frequency change
Number of subjects: 0
Study: 2499481

Group type: EXPERIMENTAL
Intervention: Intravenous SMS 201‐995 (1.7, 0.8, 0.2, and 0.1 micrograms min‐1 for Groups A, B, C, and D respectively)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Subcutaneous SMS 201‐995 (25 micrograms for Group E)
Number of subjects: 25

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 25
Study: 370535

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose cyclophosphamide
Number of subjects: 0
Study: 30291181

Group type: EXPERIMENTAL
Intervention: Virtual outpatient clinic (VOPC)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Actual outpatient clinic (OPC)
Number of subjects: 209
Study: 27696012

Group type: EXPERIMENTAL
Intervention: Intermittent anticoagulation using NOACs for 48 hours to 1 week based on daily ECG monitoring; patients transmitted daily ECGs using an iPhone-based device.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Continuous anticoagulation using NOACs.
Number of subjects: 58
Study: 26092816

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (OFS)
Number of subjects: 4717

Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian function suppression (OFS)
Number of subjects: 4717
Study: 24245553

Group type: EXPERIMENTAL
Intervention: Educational course in skin-protective behaviour and written information about skin care, with access to usual care and treatment.
Number of subjects: 742
Study: 21262044

Group type: EXPERIMENTAL
Intervention: Brief intervention designed to increase the rate of secure infant attachment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 0
Study: 18567877

Group type: EXPERIMENTAL
Intervention: 2 g/kg of IVIG over 2 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 51
Study: 16484440

Group type: EXPERIMENTAL
Intervention: Ketorolac (KETO)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NG-nitro-L-arginine methyl ester (L-NAME)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of KETO and L-NAME
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control site (Ringer solution)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Local heating with KETO
Number of subjects: 13

Group type: COMPARATOR
Intervention: Local heating with L-NAME
Number of subjects: 13
Study: 12547382

Group type: EXPERIMENTAL
Intervention: Pain anxiety
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fear of negative evaluation
Number of subjects: 70
Study: 10846252

Group type: EXPERIMENTAL
Intervention: Zinc gluconate regimen with constant dose
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Zinc gluconate regimen with initial loading dose
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional therapeutic regimen of two capsules daily for three months
Number of subjects: 67
Study: 9109283

Group type: EXPERIMENTAL
Intervention: Participative goal setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assigned goal setting
Number of subjects: 0
Study: 8257138

Group type: EXPERIMENTAL
Intervention: 100 mg AZT with breakfast (B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 250 mg AZT with breakfast (B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 100 mg AZT fasting (F)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 250 mg AZT fasting (F)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 100 mg AZT breakfast (B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 250 mg AZT breakfast (B)
Number of subjects: 27
Study: 2931047

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin as two 250‐mg tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin as one 500‐mg tablet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ciprofloxacin solution
Number of subjects: 18
Study: 30849341

Group type: EXPERIMENTAL
Intervention: Graft dislocation (GD)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No graft dislocation (GD)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Early acutely elevated postoperative IOP
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No early acutely elevated postoperative IOP
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: History of elevated postoperative IOP beyond 1 month
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No history of elevated postoperative IOP beyond 1 month
Number of subjects: 1090
Study: 29936600

Group type: EXPERIMENTAL
Intervention: General anesthesia with epidural anesthesia (group GE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia alone (group G)
Number of subjects: 90
Study: 27146169

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 2

Group type: COMPARATOR
Intervention: Insufficient s‐25[OH]D <50 nmol/L
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sufficient s‐25[OH]D >80 nmol/L
Number of subjects: 2
Study: 22672713

Group type: EXPERIMENTAL
Intervention: Internal conical connection with back-tapered collar and platform shifting design
Number of subjects: 34

Group type: COMPARATOR
Intervention: External-hexagon implants with flat-to-flat implant-abutment interface
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both implant designs
Number of subjects: 34
Study: 22520306

Group type: EXPERIMENTAL
Intervention: Blue light-filtering IOL (Oculaid PC 440Y Orange Series)
Number of subjects: 22

Group type: COMPARATOR
Intervention: UV light-filtering IOL (Oculaid PC 430 Elite Series)
Number of subjects: 22
Study: 21085758

Group type: EXPERIMENTAL
Intervention: Endoscopic left thoracic sympathetic blockade
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 18543158

Group type: EXPERIMENTAL
Intervention: Dynamic treatment protocol (passive extension with a rubber band system)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Active treatment protocol (early active extension of the thumb)
Number of subjects: 21
Study: 15967908

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open surgery with 4 mg . kg(‐1) . min(‐1) dextrose infusion
Number of subjects: 12
Study: 12623838

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg IV on day 1) + IL-2 (0.25 to 3 x 10^6 IU/m2 continuous IV infusion from day 3 to day 8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pamidronate + modified IL-2 (6-hour bolus IV infusions from day 1-6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pamidronate + low-dose IL-2
Number of subjects: 19
Study: 10580431

Group type: EXPERIMENTAL
Intervention: CSII plus troglitazone (600 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSII plus metformin (1,700 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CSII alone
Number of subjects: 20
Study: 10163296

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 0
Study: 1864117

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Protriptyline
Number of subjects: 12
Study: 6888837

Group type: COMPARATOR
Intervention: lidocaine 2% with epinephrine 1:200,000
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: etidocaine 1% plain
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: etidocaine 1% with epinephrine 1:200,000
Number of subjects: 62
Study: 31142947

Group type: EXPERIMENTAL
Intervention: Oral Itraconazole for 4 weeks
Number of subjects: 320

Group type: COMPARATOR
Intervention: Oral Terbinafine for 4 weeks
Number of subjects: 320
Study: 28535154

Group type: EXPERIMENTAL
Intervention: Supplementary tube feeding immediately following tube placement
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 131
Study: 24898221

Group type: EXPERIMENTAL
Intervention: At-home bleaching system (Opalescence PF 35% Carbamide Peroxide, Ultradent)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chemically activated office bleaching system (Opalescence Xtra Boost 38% Hydrogen Peroxide, Ultradent)
Number of subjects: 28
Study: 23402714

Group type: EXPERIMENTAL
Intervention: Overfed (OF)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Underfed (UF)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Obese-prone (OP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Eucaloric (EU)
Number of subjects: 58
Study: 22320068

Group type: EXPERIMENTAL
Intervention: Modified fluoride toothpaste technique (n = 56)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Regular fluoride toothpaste (Control group, n = 57)
Number of subjects: 175
Study: 19825059

Group type: EXPERIMENTAL
Intervention: Auto-control mode
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 80
Study: 16428521

Group type: EXPERIMENTAL
Intervention: Miniaturized bypass systems (SBS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional CPB (cCPB)
Number of subjects: 45
Study: 15509922

Group type: EXPERIMENTAL
Intervention: Simultaneous rhinoplasty
Number of subjects: 412

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 412
Study: 11387364

Group type: EXPERIMENTAL
Intervention: 40 Gy total fractionated dose for the clinically noninvolved extended field (arm A)
Number of subjects: 376

Group type: COMPARATOR
Intervention: 30 Gy total fractionated dose for the clinically noninvolved extended field (arm B)
Number of subjects: 376
Study: 9407458

Group type: EXPERIMENTAL
Intervention: cilazapril (2 mg/day)
Number of subjects: 10
Study: 7714164

Group type: EXPERIMENTAL
Intervention: 200 or 400 mg RU486 administered on day LH+2
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no RU486 treatment)
Number of subjects: 11
Study: 2967936

Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol 0.1 mg/ipratropium 0.04 mg per puff)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duovent (2 puffs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salbutamol (0.1 mg per puff)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duovent (1, 2, and 4 puffs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duovent and Salbutamol
Number of subjects: 30
Study: 30707211

Group type: EXPERIMENTAL
Intervention: Rapid cycle deliberate practice
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reflective debriefing
Number of subjects: 46
Study: 29141041

Group type: EXPERIMENTAL
Intervention: Berry beverage (150g blueberries, 50g blackcurrant, 50g elderberry, 50g lingonberries, 50g strawberry, and 100g tomatoes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control beverage (water based, matched with respect to monosaccharides, pH, and volume)
Number of subjects: 40
Study: 26691360

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 80
Study: 23334780

Group type: EXPERIMENTAL
Intervention: Obturator and lateral femoral cutaneous nerve blockade
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Fascia iliaca blockade
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Other nerve blocks
Number of subjects: 1422
Study: 21975318

Group type: EXPERIMENTAL
Intervention: Adjuvant HAI‐FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinotecan
Number of subjects: 125

Group type: COMPARATOR
Intervention: Modern systemic chemotherapy alone
Number of subjects: 125
Study: 18471455

Group type: EXPERIMENTAL
Intervention: Stopped exercise before achieving 85% of age-specific maximal HR
Number of subjects: 12555

Group type: EXPERIMENTAL
Intervention: Increased HR at rest
Number of subjects: 12555

Group type: EXPERIMENTAL
Intervention: Attenuated HR increase
Number of subjects: 12555

Group type: EXPERIMENTAL
Intervention: Delayed HR recovery
Number of subjects: 12555

Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 12555
Study: 16436175

Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B (NB UVB 311 nm)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Psoralen ultraviolet A (PUVA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Psoralen followed by narrow band ultraviolet B (PUVB 311 nm)
Number of subjects: 35
Study: 15909609

Group type: EXPERIMENTAL
Intervention: Fructose 1.6-diphosphate (FDP) administered i.v. for 7 consecutive days
Number of subjects: 17
Study: 11352361

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9845400

Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide acetate
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (control)
Number of subjects: 2102
Study: 7925785

Group type: EXPERIMENTAL
Intervention: Movements in the 30 degrees direction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Movements in the 150 degrees direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated accelerations in 24 directions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actual accelerations produced by subjects
Number of subjects: 0
Study: 2513207

Group type: EXPERIMENTAL
Intervention: Standard metrifonate treatment (3 doses of 7.5 mg.kg‐1 at two‐weekly intervals)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Abbreviated metrifonate treatment (3 doses of 5 mg.kg‐1 in one day)
Number of subjects: 300
Study: 31241404

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 252
Study: 26849366

Group type: EXPERIMENTAL
Intervention: Human body posturizer (HBP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Physical training without HBP (exercise group)
Number of subjects: 150
Study: 25220909

Group type: EXPERIMENTAL
Intervention: Bovine pericardium membrane placed over the graft
Number of subjects: 26

Group type: COMPARATOR
Intervention: No membrane placed over the graft (Control)
Number of subjects: 26
Study: 22898035

Group type: EXPERIMENTAL
Intervention: BIIB021 600 mg twice a week (BIW)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BIIB021 400 mg three times a week (TIW)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall response rate with BIIB021
Number of subjects: 23
Study: 22040618

Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco Educational Unit (STEU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information-Motivation-Behavioral Skills model (IMB model)
Number of subjects: 0
Study: 19632547

Group type: EXPERIMENTAL
Intervention: Argentine tango dance lessons (10 sessions of 1.5 hours each over 2 weeks)
Number of subjects: 14
Study: 16314381

Group type: EXPERIMENTAL
Intervention: Outcome realizations at 6 months
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: High expectations but low attainment
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: High attainment, regardless of expectations
Number of subjects: 118
Study: 15351416

Group type: EXPERIMENTAL
Intervention: Templating system for ALPHANORM unicondylar knee prosthesis
Number of subjects: 29
Study: 11527645

Group type: EXPERIMENTAL
Intervention: GTN (0.6 mg/h/24 h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PETN (60 mg orally three times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 9419950

Group type: EXPERIMENTAL
Intervention: UDCA 600 mg per day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8513925

Group type: EXPERIMENTAL
Intervention: Partial zona dissection
Number of subjects: 199

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 199
Study: 2820289

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (cyclophosphamide, doxorubicin, vincristine alternating with etoposide (100 mg/m2 on days 1 to 3) and cisplatin (25 mg/m2 on days 1 to 3) every 3 weeks for six treatment cycles)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Standard chemotherapy (cyclophosphamide (1000 mg/m2), doxorubicin (50 mg/m2), and vincristine (2 mg) every 3 weeks for six courses)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 289
Study: 30374055

Group type: EXPERIMENTAL
Intervention: Testing for immunoglobulin M (IgM) and G (IgG) responses against 20 microbes associated with TBD
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Testing for Borrelia and other related TBD microbes
Number of subjects: 432
Study: 26799451

Group type: EXPERIMENTAL
Intervention: Topical 25% sodium metabisulfite
Number of subjects: 4
Study: 25792583

Group type: EXPERIMENTAL
Intervention: Patients undergoing dialysis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (N=25)
Number of subjects: 53
Study: 23852652

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 2
Study: 19940781

Group type: EXPERIMENTAL
Intervention: American Gastroenterological Association colonoscopy educational pamphlet (group I)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard prep instructions only (group P)
Number of subjects: 106
Study: 18501650

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol (15 microg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Racemic formoterol DPI (12 microg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Racemic formoterol DPI (24 microg)
Number of subjects: 39
Study: 16034446

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 30 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 60 mg
Number of subjects: 9
Study: 14512180

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg/day start, tapering doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (equivalent amounts of normal saline)
Number of subjects: 36
Study: 11022398

Group type: EXPERIMENTAL
Intervention: Tryptophan (2 to 4 g per day) with fluoxetine (20 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo with fluoxetine (20 mg per day)
Number of subjects: 30
Study: 8774267

Group type: EXPERIMENTAL
Intervention: Open cholecystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0